Chemomab Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	7.08	11.56	6.03	1.29	6.25	5.52	3.16	2.26
Research & Development	18.38	16.98	6.33	4.68	13.3	7.51	6.23	2.38
Other Operating Expenses	0	0	0	0	3.35	0	0	0
Operating Expenses	25.46	28.53	12.37	5.97	22.9	13.04	9.39	4.64
Operating Income	-25.46	-28.53	-12.37	-5.97	-22.9	-13.04	-9.39	-4.64
Interest Expense / Income	0	0	0	0	4.23	0.46	-0.09	0.04
Other Expense / Income	-1.24	-0.35	0.11	-0.02	-	-	0.18	-0.07
Pretax Income	-24.22	-28.18	-12.48	-5.95	-27.12	-13.49	-9.48	-4.61
Income Tax	0	-0.53	0	0	0	0.31	0.32	0.14
Net Income	-24.22	-27.65	-12.48	-5.95	-27.12	-13.8	-9.81	-4.74
Shares Outstanding (Basic)	235	228	207	137	9	3	8	-
Shares Outstanding (Diluted)	235	228	207	137	9	3	-	-
Shares Change	3.26%	9.70%	51.71%	1488.06%	172.65%	-61.55%	-	-
EPS (Basic)	-2.06	-2.42	-1.20	-0.88	-63.20	-87.20	-87.20	-69.60
EPS (Diluted)	-2.06	-2.42	-1.20	-0.88	-63.20	-87.20	-87.20	-69.60
Free Cash Flow	-23.61	-20.44	-11.61	-5.28	-16.55	-14.44	-8.55	-3.81
Free Cash Flow Per Share	-2.01	-1.80	-1.12	-0.77	-38.44	-91.41	-20.82	-
EBITDA	-24.15	-28.12	-12.44	-5.93	-22.62	-12.97	-9.52	-4.53
Depreciation & Amortization	0.07	0.06	0.03	0.02	0.28	0.07	0.05	0.04
EBIT	-24.22	-28.18	-12.48	-5.95	-22.9	-13.04	-9.57	-4.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).